Narrow Results

Pancreatic cancer cells overexpress the insulin receptor (IR) and the insulin-like growth factor-1 receptor (IGF1R). Activating these receptors, insulin and insulin-like growth factor-1 increase the growth and glycolysis of pancreatic cancer cells. The high glycolysis in pancreatic cancer cells increases whole-body energy expenditure and is therefore involved in the pathogenesis of cancer cachexia. The antagonism of IR and IGF1R may sabotage pancreatic cancer cells and attenuate cancer cachexia. Previous studies have shown that the intracellular regulating system of IR/IGF1R may be functionally interrelated to another intracellular system whose master regulator is hypoxia-inducible factor-1 (HIF-1). In this study, we investigated how the IR/IGF1R and HIF-1 systems are interrelated in pancreatic cancer cells. We also investigated whether a phytochemical, penta-O-galloyl-$\beta$-D-glucose ($\beta$-PGG), antagonizes IR/IGF1R, sabotages pancreatic cancer cells and alleviates cancer cachexia. We found in MiaPaCa2 pancreatic cancer cells that IR/IGF1R activation increased both the $\alpha$-subunit of HIF-1 and caveolin-1. This result suggests that IR/IGF1R, HIF-1$\alpha$, and caveolin-1 may constitute a feed-forward loop to mediate the effect of IR/IGF1R activation. $\beta$-PGG inhibited IR/IGF1R activity and decreased glycolytic enzymes in MiaPaCa2 and Panc-1 pancreatic cancer cells. When MiaPaCa2 cells were transplanted in athymic mice, their growth was inhibited by $\beta$-PGG or by a HIF-1$\alpha$ inhibitor, rhein. $\beta$-PGG and rhein also decreased glycolytic enzymes in the tumor grafts and reduced liver gluconeogenesis, skeletal-muscle proteolysis and fat lipolysis in the tumor carriers. Cancer-induced body-weight loss, however, was prevented by $\beta$-PGG but not rhein. In conclusion, $\beta$-PGG combats pancreatic cancer cells and cures cancer cachexia.

INDONESIA – Quintiles expands patient access for clinical trials to Indonesia.

JAPAN – Legacy Healthcare announces breakthrough clinical results in hair re-growth.

SINGAPORE – iNova Pharmaceuticals relocates Regional HQ to Singapore as part of Asia-centric reorganization.

AUSTRALIA – Silencing the bird flu gene: scientists prep live hen trials.

AUSTRALIA – Helsinn grants Specialised Therapeutics Australia (STA) rights to Anamorelin, treat cachexia-anorexia.

NORTH AMERICA – To survive, genes pick up new skills.

NORTH AMERICA – Phase III study evaluates two investigational hormone-releasing IUDs for prevention of pregnancy for up to three years.

NORTH AMERICA – Agilent Technologies introduces SureDesign.

NORTH AMERICA – Progress made towards production of biosimilar products in tobacco plants.

NORTH AMERICA – FDA approves Aerospan for asthma.

EUROPE – New technology offers improved chances for couples undergoing IVF.

EUROPE – Phase IIa Laquinimod trial results show positive data for potential use in active Crohn's Disease.

EUROPE – Pfizer donates vials of Factor IX to the World Federation of Hemophilia.

EUROPE – nViso gets research grant to study 3D facial imaging technology for healthcare applications.

EUROPE – New evidence-based 3D cell culture web portal launched by Reinnervate Ltd.

EUROPE – The social side of vaccine effectiveness.